Advertisement
Screener

INTELLIA THERAPEUTICS, INC. (NTLA) Executive Pay versus Performance: Pay versus Performance

INTELLIA THERAPEUTICS, INC. Pay versus Performance

The Pay versus Performance table from each proxy statement (Item 402(v)), as tagged in its XBRL, newest proxy first. Each proxy's own figures are kept, so a year restated in a later proxy appears once per proxy. PEO is the principal executive officer; NEO means the other named executive officers (average). Total shareholder return is the value of a $100 investment.

  • 2025-12-31: PEO total compensation $5.06M; PEO compensation actually paid $3.24M; Other NEO average total compensation $1.93M.
  • 2024-12-31: PEO total compensation $15.33M; PEO compensation actually paid $353.49K; Other NEO average total compensation $4.74M.
  • 2023-12-31: PEO total compensation $11.66M; PEO compensation actually paid $8.32M; Other NEO average total compensation $4.06M.
  • 2022-12-31: PEO total compensation $10.10M; PEO compensation actually paid -$14.07M; Other NEO average total compensation $3.92M.
Fiscal year endPEOPEO total compensationPEO compensation actually paidOther NEO average total compensationOther NEO average compensation actually paidTotal shareholder returnPeer group total shareholder returnNet incomeCompany-selected measureProxy filed
2025-12-31$5.06M$3.24M$1.93M$1.40M$16.53$187.14-$412.69M2026-04-30
2024-12-31$15.33M$353.49K$4.74M$335.18K$21.43$154.48-$519.02M2026-04-30
2023-12-31$11.66M$8.32M$4.06M$2.91M$56.05$119.22-$481.19M2026-04-30
2022-12-31$10.10M-$14.07M$3.92M-$4.88M$64.14$82.43-$474.19M2026-04-30
2021-12-31$9.77M$37.78M$6.99M$16.10M$217.35$122.18-$267.89M2026-04-30
2024-12-31$15.33M$353.49K$4.74M$335.18K$79.48$118.20-$519.02M2025-04-30
2023-12-31$11.66M$8.32M$4.06M$2.91M$207.84$118.87-$481.19M2025-04-30
2022-12-31$10.10M-$14.07M$3.92M-$4.88M$237.83$113.65-$474.19M2025-04-30
2021-12-31$9.77M$37.78M$6.99M$16.10M$806.00$126.45-$267.89M2025-04-30
2020-12-31$3.64M$19.28M$1.76M$7.48M$370.82$126.42-$134.23M2025-04-30
2023-12-31$11.66M$8.32M$4.06M$2.91M$207.84$118.87-$481.19M2024-04-29
2022-12-31$10.10M-$14.07M$3.92M-$4.88M$237.83$113.65-$474.19M2024-04-29
2021-12-31$9.77M$37.78M$6.99M$16.10M$806.00$126.45-$267.89M2024-04-29
2020-12-31$3.64M$19.28M$1.76M$7.48M$370.82$126.42-$134.23M2024-04-29
2022-12-31$10.10M-$14.07M$3.92M-$4.88M$237.83$113.65-$474.19M2023-05-01
2021-12-31$9.77M$37.78M$6.99M$16.10M$806.00$126.45-$267.89M2023-05-01
2020-12-31$3.64M$19.28M$1.76M$7.48M$370.82$126.42-$134.23M2023-05-01

Similar stocks

Stock NameCountryMarket CapPE Ratio
Celldex Therapeutics, Inc. (CLDX)United States$2.471B-9.72
ACHIEVE LIFE SCIENCES, INC. (ACHV)United States$0.806B-5.88
QuidelOrtho Corp (QDEL)United States$0.733B-0.90
Alpha Teknova, Inc. (TKNO)United States$0.500B-18.12
NEOGEN CORP (NEOG)United States$2.979B-247.49
MYRIAD GENETICS INC (MYGN)United States$0.397B-4.84
Insight Molecular Diagnostics Inc. (IMDX)United States$0.129B-3.90
IMMUCELL CORP /DE/ (ICCC)United States$0.091B116.10
BIOMERICA INC (BMRA)United States$0.011B
Q/C TECHNOLOGIES, INC. (QCLS)United States$0.008B-1.93